	US 11,933,794 B2
	Method for determining factor Xa inhibitor dosage
Cornelis Kluft, Sassenheim (NL)
Assigned to Good Biomarker Sciences B.V., Sassenheim (NL)
Appl. No. 16/761,769
Filed by Good Biomarker Sciences B.V., Sassenheim (NL)
PCT Filed Nov. 1, 2018, PCT No. PCT/NL2018/050730 § 371(c)(1), (2) Date May 5, 2020, PCT Pub. No. WO2019/088838, PCT Pub. Date May 9, 2019.
Claims priority of application No. 2019854 (NL), filed on Nov. 6, 2017.
Prior Publication US 2021/0181213 A1, Jun. 17, 2021
Int. Cl. G01N 33/86 (2006.01)

CPC G01N 33/86 (2013.01) [G01N 2333/755 (2013.01)]

6 Claims

1. A method of treating a subject having thrombosis or thrombosis risk in need of treatment with apixaban, the method comprising:

detecting Factor VIII level in a sample obtained from the subject to determine an appropriate dosage of the apixaban, and

administering to the subject:

a dose of 5 mg of apixaban per day if the Factor VIII level detected in the sample is below at least one reference value; or

a dose of 20 mg of apixaban per day if the Factor VIII level detected in the sample is above at least one reference value,

wherein the reference value is a Factor VIII level of between 100% and 200% of Factor VIII level in standard plasma.